Form 4: Akero Director Exercises Options, Boosts Stake

Akero Therapeutics Director Graham G. Walmsley exercised multiple stock options, acquiring 93,000 shares of common stock on October 8, 2025.

Summary

• Graham G. Walmsley, a Director of Akero Therapeutics, Inc. (AKRO), reported transactions on October 8, 2025.
• Walmsley exercised stock options to acquire a total of 93,000 shares of Akero Therapeutics common stock.
• The acquired shares were obtained through five separate option exercises at prices ranging from $8.13 to $26.32 per share.
• All options exercised were vested and currently exercisable.
• Following these transactions, Walmsley directly beneficially owns 93,000 shares of common stock.
• Walmsley also indirectly beneficially owns 1,200,000 shares through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where he is a managing member of their respective general partners.

Sentiment

Score: 7

Explanation: Insider buying (exercising options) is generally viewed as a positive signal, indicating confidence in the company's future prospects.

Positives

• Director Walmsley exercised a significant number of vested stock options, acquiring 93,000 shares, which typically signals confidence in the company's future performance.
• The exercise of options increases insider ownership, aligning management interests with those of shareholders.

Related Party Transactions

• Indirect beneficial ownership of 1,200,000 shares through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where the reporting person is a managing member of the general partners (Logos GP LLC and Logos Opportunities IV GP LLC).

Stakeholder Impact

• Shareholders: Increased insider ownership may signal confidence in the company's future, potentially influencing investor sentiment positively.

Key Dates

Recommendation

The exercise of stock options by a director, acquiring a significant number of shares, generally signals insider confidence in the company's future prospects. However, a Form 4 filing primarily reports a transaction and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. It serves as a positive data point for existing shareholders and those considering the stock, suggesting a 'hold' position while awaiting further fundamental analysis.

Keywords

Akero Therapeutics, AKRO, Insider Transaction, Stock Options, Director, Beneficial Ownership, Form 4